Surgery

At AAO 2022, Philip Dockery, MD, MPH, presents, "Effectiveness of corneal crosslinking in young patients."

In a presentation at the American Academy of Ophthalmology’s 2022 annual meeting in Chicago, Ines Lains, MD, PhD, detailed how adjunct treatment with intravitreal antivirals or early pars plana vitrectomy did not improve the rates of retinal detachment in patients diagnosed with acute retinal necrosis.

During a presentation at the American Academy of Ophthalmology’s 2022 annual meeting at McCormick Place in Chicago, Maria A. Guzman Aparicio, MD, and Teresa C. Chen, MD, detailed their research that found that pediatric patients have a significantly higher incidence of new-onset strabismus after tube shunt surgery for glaucoma compared with adults.

Mark Packer, MD, speaks on his 2022 AAO poster: "Safety and Effectiveness of a New FDA-Approved Dispersive Ophthalmic Viscosurgical Device."

The hour-long issue teaches the viewing ophthalmologist the technique and many modifications of intrascleral haptic fixation, an innovative approach when the capsule has been damage or is absent.

After a brief hiatus during the pandemic, the Flying Eye Hospital program returns.

The destination of Marco Island, Florida not only serves as an excellent backdrop for this year's Ophthalmology Times® EyeCon 2022 but also provides a unique opportunity for family members to see their ophthalmic loved ones in a professional light.

According to Nicole Fram, MD, around the world, corneal specialists are making the most of limited resources.

Jeremy Tan, MD, discusses the latest trends in eye trauma surgery at the Dean McGee Eye Institute.

Co-chairs Peter J. McDonnell, MD, director of the Wilmer Eye Institute at Johns Hopkins University School of Medicine in Baltimore, Maryland, and Oluwatosin U. Smith, MD, of Glaucoma Associates of Texas in Dallas break down the top reasons to attend this year's Ophthalmology Times® EyeCon 2022 in a series of video segments.

Elizabeth Yeu, MD, will highlight pearls for managing intraocular lenses in difficult cases.

Ophthalmologists should instruct their patients to pay attention to their eye health for the long term.

Medication is administered after LASIK and injectable prophylaxis during cataract surgery.

Bausch + Lomb expects to begin the distribution of the intraocular dyes in all EU countries, with the exception of Italy, during the first half of 2023. Bausch + Lomb and Alfa Instruments are also in the process of exploring regulatory requirements and approvals of the surgical dyes in other markets.

The first cases in the United States using the company’s suprachoroidal technology were performed earlier this month, and long-term clinical outcomes will be presented at the annual meeting of the American Academy of Ophthalmology in Chicago, starting Sept. 30.

For many surgeons, technology is replacing old methods , including the use of cadaver eyes.

The IOL has a hybrid design that combines the benefits of central extended depth-of-focus technology and multifocal technology that provides a continuous range of high-quality vision ranging from distance and intermediate and near vision to about 12 to 14 inches.

With a few key steps, surgeons can avert potential refractive surprises, and reduce postoperative dry eye for patients.

Reservoir restoration can re establish the normal anatomy and function of the conjunctiva.

By creating customized packages that incorporate the range of diagnostic and treatment options available, practices can simplify dry eye management and improve patients' outcomes.

Physician offers "real talk" on pros and cons that offers surgeons and patients decision-making insights.

According to the company, a study shows the non-implantable minimally invasive glaucoma surgery effectively reduces IOP and reduces need for IOP-lowering medications in patients diagnosed with open-angle glaucoma.

Anika Michael, MD, and Benjeil Edghill, MD, both ophthalmology specialists from AdvantageCare Physicians New York City, traveled to Haiti in July on a medical mission of mercy, where they evaluated and treated more than 400 patients and completed approximately 90 surgeries.

The companies note that data from Study CPN-302 confirm the results in the first Phase 3 study, CPN-301, and they demonstrate the clear benefits of treating patients after cataract surgery with APP13007.

Matthew Emanuel, MD, of Glaucoma Associates of Texas, discusses some of the current trends in cataract surgery. He notes it is something that everyone deals with as they get older. It also can be an issue for pediatric patients. Emanuel also notes that it is important for physicians to be able to educate their patients on the disease.